

Prior Authorization Request Form for
gilteritinib (Xospata)



JOHNS HOPKINS
 HEALTHCARE

7231 Parkway Drive, Suite 100, Hanover, MD 21076

USFHP Pharmacy Prior Authorization Form

To be completed by Requesting provider	
Drug Name:	Strength:
Dosage/Frequency (SIG):	Duration of Therapy:

**FAX Completed Form and
 Applicable Progress Notes to:
 (410) 424-4037**

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Step 1 Please complete patient and physician information (please print):

Patient Name: _____	Physician Name: _____
Address: _____	Address: _____
Sponsor ID # _____	Phone #: _____
Date of Birth: _____	Secure Fax #: _____

Step 2 Please complete the clinical assessment:

1. Is the patient 18 years of age or older?	<input type="checkbox"/> Yes Proceed to question 2	<input type="checkbox"/> No STOP Coverage not approved
2. Is this medication being prescribed by or in consultation with a hematologist or oncologist?	<input type="checkbox"/> Yes Proceed to question 3	<input type="checkbox"/> No STOP Coverage not approved
3. Does the patient have relapsed or refractory acute myeloid leukemia?	<input type="checkbox"/> Yes Proceed to question 4	<input type="checkbox"/> No Proceed to question 5
4. Is there laboratory evidence to confirm Ferline McDonough Sarcoma (FMS)-like tyrosine kinase 3 (FLT3) mutation, as detected by an FDA-approved test?	<input type="checkbox"/> Yes Proceed to question 7	<input type="checkbox"/> No STOP Coverage not approved
5. Please provide the diagnosis.	_____ Proceed to question 6	
6. Is the diagnosis cited in the National Comprehensive Cancer Network (NCCN) guidelines as a category 1, 2A, or 2B recommendation?	<input type="checkbox"/> Yes Proceed to question 7	<input type="checkbox"/> No STOP Coverage not approved
7. Is the patient pregnant or actively trying to become pregnant?	<input type="checkbox"/> Yes STOP Coverage not approved	<input type="checkbox"/> No Proceed to question 8

Prior Authorization Request Form for
gilteritinib (Xospata)

8. Will the patient be monitored for posterior reversible encephalopathy syndrome (PRES), prolonged QTc, and pancreatitis?

Yes
Sign and date below

No
STOP
Coverage not approved

Step 3 I certify the above is true to the best of my knowledge. Please sign and date:

Prescriber Signature

Date

[29 May 2019]

For Internal Use Only

Approved:

Duration of Approval: _____month(s)

Denied:

Authorized By:

Incomplete/Other:

PA#:

Date Faxed to MD:

Date Decision Rendered: